Targeted Internal Radiation Therapy in Advanced HCC Patients.
Not Applicable
Completed
- Conditions
- Advanced Hepatocellular CarcinomaInternal Radiation
- Interventions
- Biological: 131I-chTNT-1/B
- Registration Number
- NCT02724267
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Brief Summary
The aim of this study is to evaluate the 131I-chTNT-1/B treatment effect and safety of individual therapy using randomized controlled study, in order to acquire the evidence of evidence-based medicine and create a new program of targeted internal radiation therapy in advanced HCC patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Via clinical diagnosis and confirm it is advanced hepatocellular carcinoma
- mRECIST estimation: necrosis region in HCC
- Negative iodine allergy test
- Liver function ：Child-Pugh A/B
Exclusion Criteria
- reject to attend；
- impossible to come to our hospital for physical examination regularly.
- Blood clotting function hindrance; 4, Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction,which may affect the treatment of liver cancer.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description internal radiation group 131I-chTNT-1/B Patients will be treated with TACE combined with internal radiation. transcatheter arterial chemoembolization 131I-chTNT-1/B Patients will be treated with TACE only.
- Primary Outcome Measures
Name Time Method Overall Survival 3 years
- Secondary Outcome Measures
Name Time Method Time to Progression 3 years
Trial Locations
- Locations (1)
Eastern hepatobilliary surgery hospital
🇨🇳Shanghai, Shanghai, China